Navigation Links
Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
Date:2/12/2008

- Lead Clinical Program and Two Clinical Candidates Featured -

SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, announced four abstracts have been selected for presentation at the meeting of American Association for Cancer Research being held in San Diego on April 12-16, 2008.

"We are pleased to have this opportunity to present important data on both RAV12, Raven's lead therapeutic antibody entering Phase 2 development for the treatment of adenocarcinomas and the promising near-term clinical candidates in our oncology pipeline," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Raven will present significant new data on RAV12 supporting the chemotherapeutic synergies that inform its impending phase 2 trials. In addition, recent discoveries concerning novel epitopes and effector mechanisms associated with two new antibodies targeting cancer stem cells will be presented for the first time. Both antibodies are slated for clinical development. Finally, having advanced the technology to culture cancer stem cells on a sustained basis in vitro, we will present their in vivo biology, using prostate cancer stem cells as an important new model system for understanding the growth and metastasis of human cancer."

The presentations are scheduled as follows:

Oral Presentation in a Minisymposium Session

The anti-B7-H3-4Ig antibody TES7 recognizes cancer stem cell lines, modulates angiogenic factor secretion, and exhibits potent anti-tumor activity in vivo

Session ID: Experimental and Molecular Therapeutics 24

Date and Time: Monday, April 14, 2008, 1:00 PM

Abstract Number: 2555

Poster Sessions

Human prostate cancer stem cell line spontaneously metastasizes in vivo

Session ID: Tumor
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Amyris Biotechnologies Announces $70 Million Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 The laboratory information management ... witnessed a number of technological advancements due to factors ... growing need to integrate healthcare systems, and increasing government ... in system integration. Key players in the market focus ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... 25 Years of Life ... Sciences Industry Experience, RANCHO CORDOVA, Calif., Aug. ... innovative products that,process and store adult stem cells, said today that ... America, has been named to the Company,s Board of,Directors. Her appointment ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, will announce its second quarter 2008,financial and ... 12,2008. The Company will host a conference call ... day at 4:30 p.m., Eastern Time., Participants ...
... $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48, ... WPI ), a leading specialty pharmaceutical,company, today reported financial ... Second Quarter 2008 Results, Net revenue for the ... $60.3 million, or $0.53 per diluted share. Net income ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... were made whole again by bone tissue grown from ... defects (defects that would not otherwise heal on their ... forms the skull, is a vivid demonstration of new ... use hESCs for tissue regeneration. Using mesenchymal ...
... (December 1, 2007) Damaged or defective genes have ... cancers. Over the past decade, however, scientists have discovered ... off and can cause cancer without any changes in ... poorly understood. Researchers in the laboratory of ...
... Water chemistry and mineralogy are scientific fields that have ... technologies. The boundary of water and rock, however, is ... field of nanoparticle science. Scientists are discovering that ... and engineered water chemistry and systems differently than similar ...
Cached Biology News:Human embryonic stem cell -- derived bone tissue closes massive skull injury 2DNA methylation shown to promote development of colon tumors 2DNA methylation shown to promote development of colon tumors 3Between water and rock -- a new science 2Between water and rock -- a new science 3Between water and rock -- a new science 4Between water and rock -- a new science 5
...
... siSolutions siRNA Custom Synthesis Service ... duplex RNA to knockdown any ... (19 RNA base pairs with ... 27-mers, or other lengths of ...
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
...
Biology Products: